Investment Thesis
ENvue Medical exhibits severe fundamental deterioration with negative gross margins (-8.4%), indicating unsustainable unit economics where losses accumulate on every sale. Operating cash burn of $4.3M annually against only $2.2M cash reserves provides less than 6 months of runway, while near-zero revenue ($653K) and liquidity stress (0.90x current ratio) signal existential operational challenges.
Strengths
- Low debt burden with 0.04x debt-to-equity ratio providing financial flexibility
- Improved EPS trend with 80.6% YoY improvement suggesting losses are narrowing
- Stockholders' equity of $32M provides base assets and dilution cushion
Risks
- Negative gross margin of -8.4% indicates broken unit economics with losses on every sale
- Operating cash outflow of $4.3M with only $2.2M cash creates sub-6-month runway
- Liquidity crisis emerging with current ratio of 0.90x and quick ratio of 0.57x
- Minimal revenue base of $653K suggests complete lack of market traction or commercialization failure
- Negative operating margin of -568.3% reflects severe operational dysfunction
Key Metrics to Watch
- Gross margin trend and path to positive unit economics
- Cash runway depletion rate and next capital raise timeline
- Revenue growth trajectory and customer acquisition metrics
- Operating cash flow stabilization and burn rate reduction
- Quarterly cash position changes and liquidity developments
Financial Metrics
Revenue
653.0K
Net Income
-3.8M
EPS (Diluted)
$-6.88
Free Cash Flow
-4.3M
Total Assets
39.9M
Cash
2.2M
Profitability Ratios
Gross Margin
-8.4%
Operating Margin
-568.3%
Net Margin
-585.3%
ROE
-11.9%
ROA
-9.6%
FCF Margin
-662.9%
Balance Sheet & Liquidity
Current Ratio
0.90x
Quick Ratio
0.57x
Debt/Equity
0.04x
Debt/Assets
19.7%
Interest Coverage
-18.84x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-21T07:43:10.993617 |
Data as of: 2026-03-31 |
Powered by Claude AI